PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Holmen Olofsson, G.* ; Idorn, M.* ; Carnaz Simões, A.M.* ; Aehnlich, P.* ; Skadborg, S.K.* ; Nößner, E. ; Debets, R.* ; Moser, B.* ; Met, Ö.* ; Thor Straten, P.*

Vγ9Vδ2 T cells concurrently kill cancer cells and cross-present tumor antigens.

Front. Immunol. 12:645131 (2021)
Postprint DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The human Vγ9Vδ2 T cell is a unique cell type that holds great potential in immunotherapy of cancer. In particular, the therapeutic potential of this cell type in adoptive cell therapy (ACT) has gained interest. In this regard optimization of in vitro expansion methods and functional characterization is desirable. We show that Vγ9Vδ2 T cells, expanded in vitro with zoledronic acid (Zometa or ZOL) and Interleukin-2 (IL-2), are efficient cancer cell killers with a trend towards increased killing efficacy after prolonged expansion time. Thus, Vγ9Vδ2 T cells expanded for 25 days in vitro killed prostate cancer cells more efficiently than Vγ9Vδ2 T cells expanded for 9 days. These data are supported by phenotype characteristics, showing increased expression of CD56 and NKG2D over time, reaching above 90% positive cells after 25 days of expansion. At the early stage of expansion, we demonstrate that Vγ9Vδ2 T cells are capable of cross-presenting tumor antigens. In this regard, our data show that Vγ9Vδ2 T cells can take up tumor-associated antigens (TAA) gp100, MART-1 and MAGE-A3 - either as long peptide or recombinant protein - and then present TAA-derived peptides on the cell surface in the context of HLA class I molecules, demonstrated by their recognition as targets by peptide-specific CD8 T cells. Importantly, we show that cross-presentation is impaired by the proteasome inhibitor lactacystin. In conclusion, our data indicate that Vγ9Vδ2 T cells are broadly tumor-specific killers with the additional ability to cross-present MHC class I-restricted peptides, thereby inducing or supporting tumor-specific αβTCR CD8 T cell responses. The dual functionality is dynamic during in vitro expansion, yet, both functions are of interest to explore in ACT for cancer therapy.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
7.561
1.573
7
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Apc Or Antigen Presenting Cells ; Vγ9vδ2 T Cells ; Antigen Cross-presentation ; Cancer ; Cancer Killing ; γδ Or Gamma Delta T Cells; Real-time; Activation; Tcr; Identification; Immunotherapy; Proliferation; Cytotoxicity; Specificity; Receptors; Expansion
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 1664-3224
e-ISSN 1664-3224
Zeitschrift Frontiers in Immunology
Quellenangaben Band: 12, Heft: , Seiten: , Artikelnummer: 645131 Supplement: ,
Verlag Frontiers
Verlagsort Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-502710-001
Förderungen Dansk Kraeftforskningsfond
Danish Council for Independent Research
A.P. Moller foundation
Dagmar Marshalls Foundation
Aase and Ejnar Danielsen Foundation
Danish Cancer Society
DOI 10.3389/fimmu.2021.645131
WOS ID WOS:000661846500001
Scopus ID 85108112296
PubMed ID 34149689
Erfassungsdatum 2021-07-13
[➜Korrektur melden]